Systemic Hormones and Muscle Protein Synthesis
Sarcopenia, Muscle Hypotrophy, Muscle Atrophy
About this trial
This is an interventional basic science trial for Sarcopenia focused on measuring Protein Synthesis, Hypertrophy, Testosterone
Eligibility Criteria
Inclusion Criteria:
Young (18-30y) and old (60-75y) males who are generally healthy
Exclusion Criteria:
- Participation in a formal exercise regime
- BMI < 18 or > 30 kg·m2
Active cardiovascular disease:
- uncontrolled hypertension (BP > 160/100),
- angina,
- heart failure (class III/IV),
- arrhythmia,
- right to left cardiac shunt,
- recent cardiac event
- Taking beta-adrenergic blocking agents, statins, non-steroidal anti-inflammatory drugs or HRT
Cerebrovascular disease:
- previous stroke,
- aneurysm (large vessel or intracranial)
- epilepsy
Respiratory disease including:
- pulmonary hypertension,
- COPD,
- asthma,
Metabolic disease:
- hyper and hypo parathyroidism,
- Hypo and hyper gonadism
- untreated hyper and hypothyroidism,
- Cushing's disease,
- type 1 or 2 diabetes
- Active inflammatory bowel or renal disease
- Malignancy
- Altered hormonal profile
- Recent steroid treatment (within 6 months) or hormone replacement therapy
- Clotting dysfunction
- Musculoskeletal or neurological disorders
- Family history of early (<55y) death from cardiovascular disease
Sites / Locations
- Royal Derby Hospital Medical School
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Old Testosterone trained
Old Placebo trained
Young Zoladex trained
Young placebo trained
8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks) Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection
8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.
8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study) Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician.
8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.